Precision BioSciences Files More Lawsuits Against Cellectis Alleging Patent Infringement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision BioSciences today announced that it has filed two more patent infringement lawsuits against French firm Cellectis.

The lawsuits were filed in US District Court for the Eastern District of North Carolina and allege Cellectis infringes US Patent Nos. 8,119,381 and 8,119,361. The patents relate to Precision Bio's Directed Nuclease Editor genome engineering technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.